Equities research analysts at StockNews.com started coverage on shares of Danaher (NYSE:DHR – Get Free Report) in a report issued on Wednesday. The firm set a “buy” rating on the conglomerate’s stock.
Other analysts also recently issued research reports about the company. Stifel Nicolaus dropped their price target on Danaher from $250.00 to $240.00 and set a “hold” rating for the company in a research report on Wednesday, July 26th. Bank of America lifted their price target on Danaher from $250.00 to $280.00 in a research report on Wednesday, July 26th. JPMorgan Chase & Co. dropped their target price on Danaher from $260.00 to $250.00 and set an “overweight” rating for the company in a research report on Wednesday, October 25th. Raymond James dropped their target price on Danaher from $250.00 to $240.00 and set an “outperform” rating for the company in a research report on Wednesday, October 25th. Finally, KeyCorp dropped their target price on Danaher from $300.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, October 25th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $257.73.
Danaher Stock Up 3.8 %
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, October 24th. The conglomerate reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.19. The firm had revenue of $6.87 billion during the quarter, compared to the consensus estimate of $6.60 billion. Danaher had a return on equity of 13.71% and a net margin of 20.01%. The company’s revenue for the quarter was down 10.3% on a year-over-year basis. During the same quarter last year, the company posted $2.56 EPS. Research analysts anticipate that Danaher will post 8.36 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $250.54, for a total value of $147,818.60. Following the sale, the senior vice president now directly owns 6,939 shares of the company’s stock, valued at $1,738,497.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich raised its stake in Danaher by 100,144.5% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,184,308,095 shares of the conglomerate’s stock valued at $284,233,943,000 after purchasing an additional 1,183,126,676 shares during the period. State Street Corp raised its stake in Danaher by 3.2% during the 2nd quarter. State Street Corp now owns 27,962,346 shares of the conglomerate’s stock valued at $6,718,427,000 after purchasing an additional 866,600 shares during the period. Moneta Group Investment Advisors LLC raised its stake in Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock valued at $6,180,839,000 after purchasing an additional 23,262,904 shares during the period. Capital International Investors increased its stake in Danaher by 20.4% in the 2nd quarter. Capital International Investors now owns 14,029,348 shares of the conglomerate’s stock worth $3,366,677,000 after acquiring an additional 2,377,625 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Danaher by 4.3% in the 2nd quarter. Geode Capital Management LLC now owns 13,459,741 shares of the conglomerate’s stock worth $3,221,386,000 after acquiring an additional 559,056 shares during the last quarter. 76.71% of the stock is owned by hedge funds and other institutional investors.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
- Five stocks we like better than Danaher
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Analyst says Archer Aviation may double. Is it time to buy?
- 3 Healthcare Dividend Stocks to Buy
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- How to Invest in Hotel Stocks
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.